Class / Patent application number | Description | Number of patent applications / Date published |
514210910 | 2 amino acid residues in the peptide chain | 50 |
20100240599 | ANTIOXIDANT CONSTITUENTS - An object of the present invention is to provide an antioxidant composition that is effective in the living body against active oxygen species produced in the body. The present invention provides an antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals, with respect to active oxygen species produced in the body, the antioxidant composition comprising a mixture in which at least 20 mg of vitamin C (L-ascorbic acid or sodium L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s), at least 10 mg of polyphenyol compound(s) or at least 1.5 mg of carotenoid compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof obtained from animal extract as an agent for scavenging hypochlorite active oxygen. | 09-23-2010 |
20100298242 | MASKING THE TASTE OF COMPOSITONS CONTAINING SALT - The invention relates to the use of sweeteners for masking the salty taste of compositions as well as compositions containing salt and defined sweeteners, the amount of sweeteners being suitable for masking the salty taste of the composition. | 11-25-2010 |
20100323975 | THERAPEUTIC AGENT FOR CEREBRAL ISCHEMIC INJURY - A therapeutic agent for cerebral ischemic injury contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine as an active ingredient. The therapeutic agent for cerebral ischemic injury preferably has a dosage form as an injection for intravenous administration. The therapeutic agent for cerebral ischemic injury having a dosage form as an aqueous injection contains at least one selected from L-alanyl-L-histidine and glycyl-L-histidine at a concentration of preferably 0.3 to 3.5 mol/L, and more preferably 0.6 to 2.1 mol/L. | 12-23-2010 |
20110009346 | Methods and compositions for increasing the anaerobic working capacity in tissues - Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine. | 01-13-2011 |
20110071093 | Novel Reagents - Oligomeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble, non-peptidic oligomer and a pharmaceutically active agent. The oligomeric reagents are useful for, among other things, forming oligomer active agent conjugates. Related methods, compositions, preparations, and so forth are also provided. | 03-24-2011 |
20110086809 | Enteral Administration Of Arginine-Glutamine Dipeptide To Support Retinal, Intestinal, Or Nervous System Development - A method for supporting retinal, intestinal, and/or nervous system development in a neonate is provided. The method involves enterally administering arginine-glutamine dipeptide to a neonate. | 04-14-2011 |
20110105417 | Drug Conjugates - Conjugated compounds comprising a therapeutic or diagnostic agent linked to a substrate for a cell membrane transporter or receptor by lipophilic linker are provided. | 05-05-2011 |
20110124585 | Dimeric Small Molecule Potentiators of Apoptosis - Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology. | 05-26-2011 |
20110130350 | SYNTHESIS SCHEME FOR LACOSAMIDE - The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the 0-methylation of a compound of formula (I) to produce a compound of formula (II) in a single step reaction. | 06-02-2011 |
20110224154 | PEPTIDE DERIVATIVE AND COMPOSITION FOR PROMOTING TEAR SECRETION COMPRISING THE SAME - A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition for promoting lacrimal secretion comprising a peptide derivative represented by the formula (I): | 09-15-2011 |
20110245189 | COMPOSITION AND METHOD FOR THE TREATMENT OF EYE DISEASE - Embodiments of the invention disclosed herein relate to compositions comprising carnosine and N-acetyl-histitidine in a pharmaceutically acceptable carrier. Other embodiments disclosed herein relate to preventing and/or ameliorating one or more symptoms associated with an eye disease such as dry eye syndrome, cataracts of the eye and nuclear sclerosis of the eye lens. Kits for preventing and/or ameliorating one or more symptoms associated with an eye disease by administering a pharmaceutical composition comprising N-acetyl-histidine are also disclosed. | 10-06-2011 |
20110312902 | CYTOPROTECTIVE THEREAPEUTIC AGENTS FOR THE PREVENTION OF REPERFUSION INJURY FOLLOWING ISCHEMIC STROKE - The present invention relates generally to the use of γ-glutamyl antioxidants, particularly γ-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The γ-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the reverse movement of Na/Ca exchange in the blood-brain barrier such as 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulphonate (KB-R7943). | 12-22-2011 |
20120077759 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation - Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described. | 03-29-2012 |
20120083457 | Bortezomib Formulations - A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture. | 04-05-2012 |
20120149653 | MULTIFUNCTIONAL LINKERS AND METHODS FOR THE USE THEREOF - In accordance with the present invention, novel multifunctional compounds have been developed which have orthogonal reactive groups thereon, thereby facilitating preparation of compounds having multiple functional properties (e.g., a targeting moiety and a biologically active moiety). Such constructs are useful for a variety of applications, e.g., for the delivery of biologically compatible materials, and release thereof in active form. Therefore, in accordance with the present invention, there are provided multifunctional linkers of defined structure, as well as various derivatives thereof bearing one or more biologically active components thereon. Also provided in accordance with the present invention are methods for the preparation of such constructs, as well as various uses thereof. | 06-14-2012 |
20120245106 | MODIFIED LYSINE-MIMETIC COMPOUNDS - Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed. | 09-27-2012 |
20120252743 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA - The invention provides methods of making and using compounds of the formula: | 10-04-2012 |
20120277168 | KOKUMI-IMPARTING AGENT - A substance capable of imparting a kokumi having CaSR agonist activity is described. This substance is able to impart kokumi in a superior manner, in particular, at the initial taste, and is also highly stable and can easily be produced at a low cost. The present invention thus provides a kokumi-imparting composition which includes such a substance as well as a complex kokumi-imparting composition which includes the substance and other substances possessing the CaSR agonist activities in combination. More particularly, the present invention herein provides a kokumi-imparting composition including γ-Glu-Nva (L-γ-glutamyl-L-norvaline), and a complex kokumi-imparting composition including the foregoing substance and another substance having a CaSR agonist activity, in combination. | 11-01-2012 |
20120322749 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 12-20-2012 |
20130045929 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN - The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan. | 02-21-2013 |
20130045930 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN - The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 2 (polymorphic form I) of the mono-sodium salt of D-isoglutamyl-D-tryptophan. | 02-21-2013 |
20130059800 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES - Pyrrolobenzodiazepine dimers I having a C2-C3 double bond and an aryl group at the C2 position on one monomer unit, and a C2-C3 double bond and either a conjugated double or triple bond at the C2 position or an alkyl group at the C2 position on the other monomer unit, and conjugates of these compounds. | 03-07-2013 |
20130225509 | METHOD TO ENHANCE ENDURANCE - The present invention relates to a method of enhancing endurance of a human subject through administration of alanyl-glutamine or alanyl-glutamine salt. | 08-29-2013 |
20130225510 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS - The invention provides an orally-administrable nutritional product comprising a dipeptide including a branched chain amino acids (BCAA). In one embodiment, the nutritional product comprises a dipeptide selected from at least one of the following: alanyl-leucine, alanyl-isoleucine, alanyl-valine, glycyl-leucine, glycyl-isoleucine, and glycyl-valine. | 08-29-2013 |
20130225511 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES - The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions. | 08-29-2013 |
20130225512 | DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION - Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed. | 08-29-2013 |
20130331344 | LEARNING MOTIVATION IMPROVERS - The present invention aims to provide antidepressants which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide learning motivation improvers which are useful for improvement of learning motivation and can be ingested continuously. | 12-12-2013 |
20140038910 | Beta Amino Acid Derivatives as Integrin Antagonists - Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: | 02-06-2014 |
20140094420 | HYDROGEL-FORMING MATERIAL - There is provided a hydrogel-forming material from which a hydrogel can be formed with a simpler method and under milder conditions. A hydrogel-forming material comprising a lipid peptide-type gelator that is formed of at least one selected from compound of the following formula (1): | 04-03-2014 |
20140142051 | CARBOHYDRATE-BASED PERITONEAL DIALYSIS FLUID COMPRISING GLUTAMINE RESIDUE - The present invention relates to a carbohydrate-based peritoneal dialysis fluid, containing a compound selected from the group consisting of glutamine, preferably L-glutamine; a dipeptide capable of releasing glutamine, L-glutamine in free form, preferably selected from the group consisting of glutaminyl-glycine, glycinyl-glutamine, glutaminyl-alanine, alanyl-glutamine; an oligopeptide consisting of two to seven glutamine, preferably L-glutamine residues; and mixtures thereof. The peritoneal dialysis fluids of the present invention are useful for inhibition of technical failure in a person undergoing peritoneal dialysis treatment. | 05-22-2014 |
20140256655 | PRODUCTS AND METHODS FOR AORTIC ABDOMINAL ANEURYSM - This invention relates to the treatment of aortic abdominal aneurysm. In particular, the invention relates to products and methods that inhibit Notch signaling to treat a patient developing or suffering from an aortic abdominal aneurysm. | 09-11-2014 |
20140274917 | Compositions and Methods for Treating Ischemia and Ischemia-Reperfusion Injury - The present invention relates to compositions comprising a substantially pure compound represented by Structural Formula I: | 09-18-2014 |
20140342997 | COMPLEX-FORMING COMPOUNDS - Present invention refers to complex-forming compounds of the general formula | 11-20-2014 |
20150011484 | PRODRUGS OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN AND D-GAMMA-GLUTAMYL-L-TRYPTOPHAN - The present invention provides pro-drugs of D-gamma-glutamyl-[D/L]-tryptophan, said pro-drugs are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein G is C | 01-08-2015 |
20150031636 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES - The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions. | 01-29-2015 |
20150031637 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER - The present invention relates to a combination comprising a substance with inhibiting effect on the ileal bile acid transport system (IBAT) and at least one other active substance selected from an IBAT inhibitor; an enteroendocrine peptide or enhancer thereof; a dipeptidyl peptidase-IV inhibitor; a biguanidine; an incretin mimetic; a thiazolidinone; a PPAR agonist; a HMG Co-A reductase inhibitor; a bile acid binder; and a TGR5 receptor modulator; wherein the IBAT inhibitor compound and the at least one other active substance are administered simultaneously, sequentially or separately. | 01-29-2015 |
20150045312 | Use of Compounds Elevating Glutathione Levels for the Treatment of Autism, Autistic Spectrum Disorders and Fragile X Syndrome - Methods of treating autism, autistic spectrum disorders or Fragile X syndrome comprised of administering molecules that engage the cystine-glutamate exchange (System x | 02-12-2015 |
20150051161 | Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease - The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease. In particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes. | 02-19-2015 |
20150126462 | PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA - The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine. | 05-07-2015 |
20150141352 | BONE LOSS PREVENTING AND BONE REGENERATION OR BONE FORMATION PROMOTING PHARMACEUTICAL COMPOSITION COMPRISING MURAMYL DIPEPTIDE - The present invention relates to a bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide, an analogue thereof, a derivative thereof or a pharmaceutically acceptable salt thereof. In contrast to existing passive therapeutic agents which center on bone absorption suppression based on mechanisms for reducing osteoclast functionality, the composition comprising muramyl dipeptide of the present invention promotes the differentiation of osteoblasts, which are bone forming cells, and can advantageously be used in various diseases where bone formation is required as an active therapeutic agent that does not affect osteoclast. | 05-21-2015 |
20150290276 | METHODS OF TREATING MUSCULAR DYSTROPHY - Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed. | 10-15-2015 |
20150290277 | PHARMACEUTICAL COMPOSITION - The present invention relates to a parenteral pharmaceutical composition comprising therapeutically effective amounts of N-(2-pyrazine) carbonyl-L-phenylalanine-L-leucine boronic acid or its salts or its derivatives and tromethamine wherein the composition is stable. | 10-15-2015 |
20150299250 | MACROCYCLIC COMPOUNDS AND USES THEREOF - The present invention relates to novel macrocyclic compounds of Formula I and their use as novel therapeutic agents for example as novel compounds used in methods of preventing and/or treating a disease, condition or state in a subject associated with dysregulation of protease activity and/or dysregulation of proteosome activity | 10-22-2015 |
20150329519 | Formulations Comprising Lipoyl Compounds - Provided herein are aqueous pharmaceutical formulations comprising monomeric lipoyl compounds, such as compounds of Structural Formula I: | 11-19-2015 |
20150335761 | COMPOSITIONS AND METHODS FOR CONTRACEPTION - The invention generally relates to novel compounds, compositions, devices and methods for contraception. More particularly, the invention relates to cytotoxic agents and di-peptide conjugated contraceptive agents, methods for their preparation, pharmaceutical compositions, devices and uses thereof, especially in the prevention of pregnancy. | 11-26-2015 |
20160175261 | METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANES | 06-23-2016 |
20160187320 | ASSAY FOR SCREENING COMPOUNDS THAT SELECTIVELY DECREASE THE NUMBER OF CANCER STEM CELLS - The present invention provides, inter alia, a method for identifying an agent that selectively decreases the number of cancer stem cells (CSCs). This method includes (a) contacting a CSC from a population of cells with a candidate agent; and (b) determining whether the candidate agent reduces the survival or growth of the CSC or increases differentiation of the CSC relative to a CSC that has not been contacted with the candidate agent. The method may be used as a high throughput screen. | 06-30-2016 |
20160193277 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | 07-07-2016 |
20160194353 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | 07-07-2016 |
20180022776 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | 01-25-2018 |